BANK VONTOBEL/CALL/NOVO NORDISK ADR B/120/0.1/21.06.24 | Delayed Deutsche Boerse AG 11:15:22 09/05/2024 pm IST | ||
| 1.03 EUR | +10.75% |
|
| Current month | -21.19% | ||
| 1 month | -18.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/24/09 | 1.03 | +10.75% | 0 |
| 08/24/08 | 0.93 | -1.06% | 0 |
| 07/24/07 | 0.94 | +28.77% | 0 |
| 06/24/06 | 0.73 | +4.29% | 0 |
| 03/24/03 | 0.7 | -19.54% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 09, 2024 at 11:15 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM31BK |
| ISIN | DE000VM31BK8 |
| Date issued | 16/10/2023 |
| Strike | 120 $ |
| Maturity | 21/06/2024 (43 Days) |
| Parity | 10 : 1 |
| Emission price | 0.65 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.91 € |
|---|---|
| Lowest since issue | 0.196 € |
| Spread | 0.01 € |
| Spread % | 0.96% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
- Stock Market
- Warrants
- Warrant